The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).
A. Oliver Sartor
Consultant or Advisory Role - Algeta
Daniel Heinrich
Consultant or Advisory Role - Algeta
Svein Inge Helle
No relevant relationships to disclose
Joe M. O'Sullivan
No relevant relationships to disclose
Sophie D. Fossa
Consultant or Advisory Role - Bristol-Myers Squibb; Sanofi
Honoraria - Amgen; Sanofi
Expert Testimony - Amgen; Sanofi
Ales Chodacki
No relevant relationships to disclose
Tomasz Demkow
No relevant relationships to disclose
John P. Logue
No relevant relationships to disclose
Mihalj Seke
No relevant relationships to disclose
Anders Widmark
No relevant relationships to disclose
Dag Clement Johannessen
No relevant relationships to disclose
Sten Nilsson
Consultant or Advisory Role - Algeta
Honoraria - Algeta
Peter Hoskin
Research Funding - Algeta
Arne Solberg
No relevant relationships to disclose
Nicholas David James
Consultant or Advisory Role - Algeta
Research Funding - Algeta
Isabel Syndikus
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Clinical Care Options; Cougar Biotechnology; Dendreon; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson/Centocor; Novartis; Pfizer; Takeda/Millennium; US Oncology; Veridex
Honoraria - Amgen; ArQule; Bayer; Clinical Care Options; Cougar Biotechnology; Dendreon; Genentech; Johnson & Johnson/Centocor; Lilly; Novartis; Pfizer; Sanofi ; US Oncology; Veridex; Wilex
Research Funding - Algeta; ArQule; Cougar Biotechnology; GlaxoSmithKline; Johnson & Johnson/Centocor; Novartis; Pfizer; Takeda/Millennium; Tokai; US Oncology; Veridex; Wilex
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
Chris Parker
Consultant or Advisory Role - Algeta (U)
Honoraria - Bayer